A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib
while it is still in the body. Healthy participants will get one dose of tucatinib by mouth.
Patients will be monitored for 8-14 days after they take the dose of tucatinib.